新型口服抗菌药佐利氟达星与吉泊沙星对杭州头孢曲松耐药及/或多重耐药淋球菌的活性
该研究测定了佐利氟达星和吉泊沙星对2020-2025年杭州340株临床淋球菌的体外活性。23.2%的菌株对头孢曲松耐药,佐利氟达星MIC90为0.06 mg/L且所有菌株均敏感,吉泊沙星MIC90为2 mg/L但12.4%菌株MIC≥2 mg/L(非敏感)。
要点
- 佐利氟达星对全部受试淋球菌敏感,包括头孢曲松耐药株。
- 吉泊沙星对12.4%的菌株MIC≥2 mg/L,提示部分非敏感。
- 两种药物MIC与环丙沙星MIC无显著相关性。
核心结论
- 佐利氟达星对杭州头孢曲松高耐药背景下的淋球菌显示强效体外活性且全部菌株敏感。
- 吉泊沙星也有强效活性,但12.4%的菌株MIC≥2 mg/L为非敏感。
研究设计与样本
- 研究采用琼脂稀释法测定佐利氟达星和吉泊沙星对2020-2025年杭州收集的340株临床淋球菌分离株的MIC。
- 对gyrA、parC和gyrB喹诺酮耐药决定区进行测序。
主要发现
- 所有分离株均对环丙沙星耐药,23.2%对头孢曲松耐药。
- 佐利氟达星MIC范围为0.008-0.25 mg/L,MIC90为0.06 mg/L;未发现携带与佐利氟达星MIC升高相关的已知GyrB靶位替换(D429或K450)。
- GyrA S91F/D95G联合ParC S87R与略高的佐利氟达星野生型MIC相关(P=0.0004)。
- 吉泊沙星MIC范围为0.06-4 mg/L,MIC90为2 mg/L;42株(12.4%)MIC≥2 mg/L为非敏感。
- GyrA S91F/D95Y联合ParC S87N及GyrA S91F/D95A联合ParC D86N与略高的吉泊沙星MIC相关(P<0.0001)。
关键数值与推荐
- 佐利氟达星MIC90 0.06 mg/L(MIC范围0.008-0.25 mg/L)。
- 吉泊沙星MIC90 2 mg/L(MIC范围0.06-4 mg/L),非敏感阈值为MIC≥2 mg/L。
- 环丙沙星与佐利氟达星MIC的Spearman秩相关系数R=0.059,与吉泊沙星R=0.0077,均无相关性。
临床怎么用
- 佐利氟达星可能作为头孢曲松耐药淋球菌感染的口服治疗选择。
- 使用吉泊沙星时需注意约12%菌株体外非敏感,建议治疗前进行药敏检测。
- 两种新药进入临床后需持续开展表型和基因型耐药监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The emergence of ceftriaxone-resistant Neisseria gonorrhoeae threatens the effectiveness of this last-line empirical therapy for gonorrhoea. Zoliflodacin and gepotidacin are novel oral gyrase/topoisomerase inhibitors with distinct mechanisms of action, recently US FDA-approved for treatment of uncomplicated urogenital gonorrhoea. We evaluated their in vitro activity against contemporary multidrug-resistant N. gonorrhoeae isolates from Hangzhou, China, a region with high ceftriaxone resistance. METHODS: MICs of zoliflodacin and gepotidacin were determined by agar dilution for 340 clinical N. gonorrhoeae isolates collected in Hangzhou (2020-2025). Sequencing of gyrA, parC and gyrB quinolone resistance-determining regions (QRDRs) was performed. RESULTS: All isolates were ciprofloxacin-resistant, and 23.2% were ceftriaxone-resistant. Zoliflodacin demonstrated potent activity (MIC range, 0.008-0.25 mg/L; MIC90, 0.06 mg/L). No isolate carried known GyrB target substitutions associated with increased zoliflodacin MICs (in D429 or K450), but GyrA S91F/D95G with ParC S87R was associated with slightly higher zoliflodacin wild-type MICs (P = 0.0004). Gepotidacin MICs ranged from 0.06 mg/L to 4 mg/L (MIC90, 2 mg/L); 42 isolates (12.4%) had non-susceptible MICs ≥2 mg/L. GyrA S91F/D95Y with ParC S87N and GyrA S91F/D95A with ParC D86N were associated with slightly higher gepotidacin MICs (P < 0.0001). No Spearman's rank correlation was observed between ciprofloxacin and zoliflodacin (R = 0.059) or gepotidacin (R = 0.0077) MICs. CONCLUSIONS: Zoliflodacin demonstrated potent in vitro activity and all isolates in this high-ceftriaxone-resistance setting were categorized as susceptible. Gepotidacin also showed potent activity, but 12% of isolates displayed non-susceptible MICs (≥2 mg/L). Continuous surveillance (phenotypic and genomic susceptibility) is essential when these two novel oral therapies enter clinical practice.
引用
- Lu W, Fu Y, Lin X, et al. Activity of the novel oral antimicrobials zoliflodacin and gepotidacin against ceftriaxone-resistant and/or multidrug-resistant Neisseria gonorrhoeae isolates from Hangzhou, China. J Antimicrob Chemother. 2026. PMID: 42809459. doi:10.1093/jac/dkag330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。